Concordant KRAS Mutations in Primary and Metastatic Colorectal Cancer Tissue Specimens: A Meta-Analysis and Systematic Review
Concordant KRAS Mutations in Primary and Metastatic Colorectal Cancer Tissue Specimens: A Meta-Analysis and Systematic Review
复制标题
DOI：
10.3109/07357907.2012.732159
复制
发表时间：
2012-12-01
影响因子：
2.4
通讯作者：
Zou, Hua-Wei
中科院分区：
文献类型：
--
作者：
Han, Cheng-Bo;Li, Fan;Zou, Hua-Wei
进行了一项荟萃分析，比较原发性和转移性结直肠癌组织样本中的KRAS基因突变。共有19篇关于986例配对原发性和远处转移以及171例配对原发性和淋巴结转移的出版物表明，KRAS基因型在原发性和远处转移肿瘤中高度一致，这表明任何一种类型的肿瘤组织都可以作为检测KRAS突变的来源，用于选择抗egfr治疗。然而，淋巴结转移肿瘤可能不适合用于KRAS突变的诊断分析，因为原发肿瘤和淋巴结转移肿瘤的发生率明显不一致。
A meta-analysis was performed to compare KRAS gene mutations in colorectal cancer tissue samples with primary and metastatic colorectal cancers. A total of 19 publications with 986 paired primary and distant metastases and 171 paired primary and lymph node metastases showed that KRAS genotype was highly concordant in primary and distant metastatic tumors, indicating that either type of tumor tissue could be useful as a source to detect KRAS mutations for selection of anti-EGFR therapy. However, lymph-node-metastatic tumors might not be suitable for diagnostic analysis of KRAS mutations due to an obvious discordant rate between primary and lymph-node-metastatic tumors.